Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.

[1]  E. Ozyar,et al.  In Regard to Kim et al. , 2017, International journal of radiation oncology, biology, physics.

[2]  A. King,et al.  Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer , 2017, The New England journal of medicine.

[3]  George Fountzilas,et al.  What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Kreike,et al.  Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group , 2016, European Archives of Oto-Rhino-Laryngology.

[5]  S. Chan,et al.  The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma , 2016, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[6]  J. Chan,et al.  Use of transoral nasopharyngeal brush biopsy for Epstein–Barr virus DNA detection of local recurrence of nasopharyngeal carcinoma after radiotherapy , 2016, Head & neck.

[7]  J. W. Lam,et al.  Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma. , 2016, Chinese clinical oncology.

[8]  Ying Sun,et al.  Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy , 2015, Oncotarget.

[9]  Ying Sun,et al.  The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. , 2015, International journal of radiation oncology, biology, physics.

[10]  S. Leung,et al.  Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma , 2015, Cancer.

[11]  S. Leung,et al.  Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Ngan,et al.  Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. , 2014, Oral oncology.

[13]  Y. Shih,et al.  Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. , 2014, International journal of radiation oncology, biology, physics.

[14]  F. Feng,et al.  Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. , 2014, International journal of radiation oncology, biology, physics.

[15]  P. Gullane,et al.  Trans-Oral Brush Biopsies and Quantitative PCR for EBV DNA Detection and Screening of Nasopharyngeal Carcinoma , 2014, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[16]  Li-Zhi Liu,et al.  Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Hung-Ming Wang,et al.  Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. , 2013, Oral oncology.

[18]  A. King,et al.  Early detection of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA analysis in a surveillance program , 2013, Cancer.

[19]  K. Ang,et al.  An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma , 2013, Clinical Cancer Research.

[20]  Ying Sun,et al.  Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[21]  Y. Shih,et al.  Plasma Epstein‐Barr virus DNA screening followed by 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma , 2011, Cancer.

[22]  B. O'Sullivan,et al.  Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. , 2011, European journal of cancer.

[23]  C. Qian,et al.  The prevalence and prevention of nasopharyngeal carcinoma in China , 2011, Chinese journal of cancer.

[24]  Jin-Ching Lin,et al.  Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma , 2010, Clinical Cancer Research.

[25]  A. Hildesheim,et al.  The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. , 2009, Virus research.

[26]  S. Leung,et al.  Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Vaccher,et al.  Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. , 2006, Cancer letters.

[28]  R. J. Baatenburg de Jong,et al.  Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area , 2006, Journal of Clinical Pathology.

[29]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Zehnder,et al.  A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma , 2005, Clinical Cancer Research.

[31]  Jaap M Middeldorp,et al.  Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia , 2005, Journal of Clinical Microbiology.

[32]  Chien-Jen Chen,et al.  Evaluation of Risk Factors for Nasopharyngeal Carcinoma in High-Risk Nasopharyngeal Carcinoma Families in Taiwan , 2005, Cancer Epidemiology Biomarkers & Prevention.

[33]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[34]  L. Ting,et al.  Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy , 2004, Cancer.

[35]  S. Leung,et al.  Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. , 2004, Clinical chemistry.

[36]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Leung,et al.  Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. , 2002, Journal of the National Cancer Institute.

[38]  S. Leung,et al.  Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. , 2000, Cancer research.

[39]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[40]  J. Cooper,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Theamboonlers,et al.  Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  G. Hasçelik,et al.  Use of plasma Epstein-Barr virus DNA monitoring as a tumor marker in follow-up of patients with nasopharyngeal carcinoma: preliminary results and report of two cases. , 2007, The International journal of biological markers.